Switch theme
Sign up to access all valuation multiples
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
1998
1.5K+
Last FY Revenue $1.2B
Last FY EBITDA $56.4M
$279M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Sopharma Trading achieved revenue of $1.2B and an EBITDA of $56.4M.
Sopharma Trading expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sopharma Trading valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | XXX | $145M | XXX | XXX | XXX |
| Gross Margin | XXX | 12% | XXX | XXX | XXX |
| EBITDA | XXX | $56.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 5% | XXX | XXX | XXX |
| EBIT | XXX | $38.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | $24.3M | XXX | XXX | XXX |
| Net Margin | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | $106M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 30, 2025, Sopharma Trading's stock price is BGN 6 (or $3).
Sopharma Trading has current market cap of BGN 199M (or $120M), and EV of BGN 463M (or $279M).
See Sopharma Trading trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $279M | $120M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 30, 2025, Sopharma Trading has market cap of $120M and EV of $279M.
Sopharma Trading's trades at 0.2x EV/Revenue multiple, and 4.9x EV/EBITDA.
Equity research analysts estimate Sopharma Trading's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sopharma Trading's P/E ratio is not available.
See valuation multiples for Sopharma Trading and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $120M | XXX | $120M | XXX | XXX | XXX |
| EV (current) | $279M | XXX | $279M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 7.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 4.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSopharma Trading's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.1M for the same period.
Sopharma Trading's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sopharma Trading's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sopharma Trading and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sopharma Trading acquired XXX companies to date.
Last acquisition by Sopharma Trading was XXXXXXXX, XXXXX XXXXX XXXXXX . Sopharma Trading acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sopharma Trading founded? | Sopharma Trading was founded in 1998. |
| Where is Sopharma Trading headquartered? | Sopharma Trading is headquartered in Bulgaria. |
| How many employees does Sopharma Trading have? | As of today, Sopharma Trading has 1.5K+ employees. |
| Is Sopharma Trading publicy listed? | Yes, Sopharma Trading is a public company listed on BUL. |
| What is the stock symbol of Sopharma Trading? | Sopharma Trading trades under SFT ticker. |
| When did Sopharma Trading go public? | Sopharma Trading went public in 2008. |
| Who are competitors of Sopharma Trading? | Similar companies to Sopharma Trading include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Sopharma Trading? | Sopharma Trading's current market cap is $120M |
| Is Sopharma Trading profitable? | Yes, Sopharma Trading is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
